

Peter Savas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/478195/publications.pdf>

Version: 2024-02-01

43
papers

7,004
citations

172207

29
h-index

243296

44
g-index

45
all docs

45
docs citations

45
times ranked

12259
citing authors

#	ARTICLE	IF	CITATIONS
1	Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. <i>Lancet Oncology</i> , The, 2017, 18, 1009-1021.	5.1	716
2	Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. <i>Nature Medicine</i> , 2018, 24, 986-993.	15.2	689
3	Clinical relevance of host immunity in breast cancer: from TILs to the clinic. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 228-241.	12.5	679
4	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. <i>Advances in Anatomic Pathology</i> , 2017, 24, 311-335.	2.4	530
5	Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab. <i>JAMA Oncology</i> , 2015, 1, 448.	3.4	482
6	Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. <i>Advances in Anatomic Pathology</i> , 2017, 24, 235-251.	2.4	469
7	RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2016, 22, 1499-1509.	3.2	428
8	Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. <i>Clinical Cancer Research</i> , 2020, 26, 487-504.	3.2	355
9	Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	227
10	Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. <i>Lancet Oncology</i> , The, 2017, 18, 52-62.	5.1	225
11	Pervasive chromosomal instability and karyotype order in tumour evolution. <i>Nature</i> , 2020, 587, 126-132.	13.7	221
12	The genomic landscape of breast cancer and its interaction with host immunity. <i>Breast</i> , 2016, 29, 241-250.	0.9	194
13	Relevance of tumor-infiltrating lymphocytes in breast cancer. <i>BMC Medicine</i> , 2015, 13, 202.	2.3	177
14	Combined CDK4/6 and PI3K Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2017, 77, 6340-6352.	0.4	163
15	Tissue-resident memory T cells in breast cancer control and immunotherapy responses. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 341-348.	12.5	159
16	The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program – CASCADE. <i>PLoS Medicine</i> , 2016, 13, e1002204.	3.9	119
17	The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial. <i>Annals of Oncology</i> , 2018, 29, 2240-2246.	0.6	113
18	Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer. <i>Pathology</i> , 2017, 49, 141-155.	0.3	112

#	ARTICLE	IF	CITATIONS
19	Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning. <i>Seminars in Cancer Biology</i> , 2018, 52, 151-157.	4.3	108
20	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 17.	2.3	106
21	Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2020, 6, 16.	2.3	90
22	Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions. <i>Frontiers in Oncology</i> , 2017, 7, 156.	1.3	87
23	Checkpoint blockade in the treatment of breast cancer: current status and future directions. <i>British Journal of Cancer</i> , 2018, 119, 4-11.	2.9	82
24	A community-based model of rapid autopsy in end-stage cancer patients. <i>Nature Biotechnology</i> , 2016, 34, 1010-1014.	9.4	66
25	Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2). <i>Science Signaling</i> , 2018, 11, .	1.6	53
26	Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer. <i>Modern Pathology</i> , 2017, 30, 952-963.	2.9	50
27	Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trial. <i>Breast</i> , 2020, 49, 55-62.	0.9	49
28	Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers. <i>Annals of Oncology</i> , 2016, 27, 1860-1866.	0.6	45
29	Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, 1335.	3.4	36
30	Identification of an excellent prognosis subset of human papillomavirus-associated oropharyngeal cancer patients by quantification of intratumoral CD103+ immune cell abundance. <i>Annals of Oncology</i> , 2019, 30, 1638-1646.	0.6	25
31	Oncogene addiction and immunity. <i>Current Opinion in Oncology</i> , 2014, 26, 562-567.	1.1	19
32	Validation and characterisation of prognostically significant PD-L1+ immune cells in HPV+ oropharyngeal squamous cell carcinoma. <i>Oral Oncology</i> , 2020, 101, 104516.	0.8	17
33	Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study. <i>Cancer Discovery</i> , 2022, 12, 2058-2073.	7.7	16
34	Molecular comparison of interval and screen-detected breast cancers. <i>Journal of Pathology</i> , 2019, 248, 243-252.	2.1	15
35	Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 25-31.	1.0	12
36	Metastatic Breast Cancer: TIL it is Too Late. <i>Clinical Cancer Research</i> , 2020, 26, 526-528.	3.2	11

#	ARTICLE	IF	CITATIONS
37	Seeing the forest and the tree: TILs and PD-L1 as immune biomarkers. Breast Cancer Research and Treatment, 2021, 189, 599-606.	1.1	11
38	Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study. Clinical Cancer Research, 2021, 27, 2159-2167.	3.2	9
39	Novel Targeted Agents and Immunotherapy in Breast Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 65-75.	1.8	8
40	Identifying oncogenic drivers associated with increased risk of late distant recurrence in postmenopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study. Annals of Oncology, 2020, 31, 1359-1365.	0.6	5
41	Combining Radiotherapy and Immunotherapy in Metastatic Breast Cancer: Current Status and Future Directions. Biomedicines, 2022, 10, 821.	1.4	5
42	Efficacy of late line pertuzumab with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer: An Australian case series. Asia-Pacific Journal of Clinical Oncology, 2019, 15, 377-382.	0.7	2
43	A phase 1 trial of 4-(N-(S-penicillaminylacetyl)amino)-phenylarsonous acid (PENAO) in patients with advanced solid tumours. Cancer Chemotherapy and Pharmacology, 2021, 87, 613-620.	1.1	0